ORDER
BEFORE THE COURT is Plaintiffs Motion for Preliminary Injunction (Dkt. 3) and the parties’ affidavits supporting and opposing the motion (Dkts. 4, 5, 14, 17, 19). 1 Having considered the parties’ submissions and the arguments of counsel at the June 2, 2010, hearing, the Court concludes that Plaintiffs motion should be GRANTED in part.
Background
Plaintiff Sound Surgical Technologies, LLC (“Plaintiff or SST”) manufactures and distributes the VASER System, which is an ultrasonic surgical system used by physicians to perform ultrasound-assisted lipoplasty. 2 Defendant Leonard A. Rubinstein, M.D., P.A. (“Rubinstein P.A.”) is a Florida corporation operating as a medical practice in Sarasota County. Defs. Ans., Dkt. 22, ¶ 2. Rubinstein, P.A. is owned and operated by Defendant Leonard A. Rubinstein, M.D. (“Rubinstein”). Id. In his practice, Rubinstein offers, among other services, cosmetic surgery, including lipoplasty. Id.; Goldberger Aff. ¶ 2.
About February 26, 2007, Plaintiff entered into a License and Use Agreement (the “LUA” [Dkt. 5 at 15-19]) with Rubinstein P.A. Id.; Dkt. 22, ¶ 14. Pursuant to the LUA, Rubinstein P.A. was granted a nonexclusive license to use Plaintiffs VASER System (or, as, as Rubinstein calls it, Plaintiffs VASER LIPOSELECTION System). The agreement also granted Rubinstein P.A. the right to use Plaintiffs registered trademark VASER 3 and Plaintiffs registered service mark LIPOSE-LECTION, 4 subject to Plaintiffs prior review and approval of any proposed use of the marks in any manner other than on marketing materials provided by Plaintiff, “including use on [Rubinstein P.A.’s] website or in other advertising or marketing material.” LUA § l.e.
The LUA provides that its initial term commences “on the date [Rubinstein P.A.] accept[s] the Equipment (the ‘Effective Date’) and continues through the last day of the 24th full calendar month following such date of acceptance” unless terminated
In their initial affidavits, John Sullivan and Daniel Goldberger, Plaintiffs chief financial officer and chief executive officer, respectively, averred that the LUA expired on March 31, 2009 with respect to one VASER System (the “first system”) and August 31, 2009 with respect to another (the “second system”). 5 As the first system was accepted on March 9, 2007 (Dkt. 5 at 23), the LUA by its terms evidently expired as to the first device on March 31, 2009. However, Goldberger and Sullivan do not explain how they derived the expiration date of August 31, 2009 for the second system. Attached to Sullivan’s affidavit and to the Complaint is a document entitled “Acceptance of Equipment” (Dkt. 5 at 20) that appears to be an acknowledgment by Rubinstein of Rubinstein P.A.’s receipt of a second VASER system. The document also acknowledges that “the date of this Acceptance ... is the Effective Date of the Agreement,” ie., of the LUA (as a notation in the margin defining the “Agreement” indicates). As the document is dated August 14, 2008, it appears to suggest that the LUA was to expire by its terms as to this VASER system on August 31, 2010 (not 2009).
Rubinstein states that, without cause, Plaintiff unilaterally terminated the LUA. 6 In his supplemental affidavit, Goldberger denies that Plaintiff terminated the LUA and avers that it “expired of its own terms on March 31, 2009 when Dr. Rubinstein failed to give notice of intent to renew after the initial 24 month term beginning April 1, 2007.” Goldberger Supp. Aff. ¶ 4. Goldberger does not repeat his and Sullivan’s averment that, as to the second system, the LUA expired on August 31, 2009. In sum, the record contains conflicting, ambiguous evidence as to when and how the LUA expired. However, all VASER Systems in Defendants’ possession have been returned to Plaintiff. Goldberger Aff. ¶ 3; Sullivan Aff. ¶ 7; see also Rubinstein Aff. at 2, 4.
About January 15, 2008, Rubinstein registered (or “reserved”) with an unspecified registrar the following eight domain names: vaserlipo.com, vaserlipo.org, vaserlipo.info, vaser-lipo.com, vaser-lipo.net, vaser-lipo.org, vaser-lipo.info, vaser-lipo.us (together, the “domain names”). Sullivan Aff. ¶ 8; see also Rubinstein Aff. at 1-2. Sullivan states that Defendants did not submit the proposed domain names to Plaintiff for prior approval and that the domain names were registered without Plaintiffs knowledge, authorization, or consent. 7 Goldberger states that no person having authority to commit Plaintiff ever authorized Rubinstein to use the VA-SER mark in any domain name or to use the VASER LIPO mark in any manner. 8
Additionally, Sullivan avers that, in the past, when a licensee physician has requested a specialized domain name directing internet traffic to the physician’s website, Plaintiff (if it approved the domain name) would register the domain name in its own name and cause the domain name to direct Internet traffic to the licensee
In their initial affidavits, Sullivan and Goldberger indicated that, as of April 8 and 12, 2010, respectively, the domain names channeled Internet traffic towww.larubinstein.com, the website for Defendants’ medical practice, where Defendants advertise a laser-assisted lipoplasty procedure that differs significantly from Plaintiffs VASER System. Sullivan Aff. ¶ 8; Goldberger Aff. ¶ 4. Rubinstein did not dispute the fact in his initial affidavit. However, in a supplemental affidavit filed after the deadline imposed by the Court’s May 10, 2010 order (Dkt. 8), Rubinstein states that, because there is no longer in effect an LUA that permits him to use Plaintiffs registered marks on his websites or other advertising relating to his medical practice, the domain names no longer direct traffic to Rubinstein’s medical practice’s website. 9 Although Rubinstein does not state when the domain names ceased channeling traffic to the website for his medical practice, Rubinstein’s counsel did not dispute Plaintiffs counsel’s representation during oral argument that the domain names continued to do so until the day before the June 2, 2010, hearing.
Rubinstein does not state that Plaintiff specifically authorized registration of the domain names. However, Rubinstein states generally that, during an unspecified period before Plaintiff filed its application to register the VASER LIPO marks (ie., before September 22, 2008, see Dkt. 5 at 11), Goldberger was aware of and consented to Rubinstein’s use of the term VASER LIPO in conjunction with Rubinstein’s use of Plaintiffs VASER System. Rubinstein Aff. at 2. Additionally, Rubinstein avers that (a) Goldberger and another authorized SST representative, James Click, were aware of and consented to Rubinstein’s use of Plaintiffs VASER mark in his advertising materials and on his websites from the inception of the LUA because (a) the LUA provision authorizing use of Plaintiffs VASER mark subject to Plaintiffs prior review and approval of any proposed use of the mark does not require that Plaintiffs approval be requested or obtained in writing and (b) when shortly after the LUA went into effect, Rubinstein met on two occasions with members of Plaintiffs national marketing and sales departments and discussed with them his marketing methods, his use of the VASER mark in his web-advertising was “was among the subjects discussed, approved and promoted.” Rubinstein Supp. Aff. at 2-3.
Rubinstein avers that in March, 2008, Goldberger initiated negotiations with Rubinstein for Plaintiffs possible purchase of the domain names from Rubinstein. Rubinstein Aff. at 2. According to Rubinstein, it was only after his refusal to sell the domain names that any question arose as to the propriety of his registration of the domain names. Id.
Goldberger states that, by June 2008 at the latest, he contacted Rubinstein to inform Rubinstein that he was using “the registered marks”
10
without permission
Standard
A party seeking a preliminary injunction must show: “(1) a substantial likelihood of success on the merits of the underlying case, (2) the movant will suffer irreparable harm in the absence of an injunction, (3) the harm suffered by the movant in the absence of an injunction would exceed the harm suffered by the opposing party if the injunction issued, and (4) an injunction would not disserve the public interest.”
Johnson & Johnson Vision Care, Inc. v. 1-800 Contacts, Inc.,
Discussion
The Lanham Act
A trademark infringement claim based on a federally registered mark un-
der Section 32(1) of the Lanham Act, 15 U.S.C. § 1114(1), requires proof: (1) that Plaintiff has a valid mark, (2) that, without authorization, Defendants used the mark or a colorable imitation thereof in commerce in connection with the sale or advertising of goods or services, and (3) that Defendants used the mark in a manner likely to confuse consumers.
See North Am. Med. Corp. v. Axiom Worldwide, Inc.,
Section 43(a) of the Lanham Act creates a federal cause of action for unfair competition by prohibiting the use in commerce of any designation likely to cause confusion (1) as to the user’s “affiliation, connection or association” with another person or (2) as to “the origin, sponsorship, or approval of [the user’s] goods, services, or commercial activities by another person.” 15 U.S.C. § 1125(a). “To establish a prima facie case of trademark infringement under § 43(a), a plaintiff must show ‘(1) that it had trademark rights in the mark or name at issue and (2) that the other party had adopted a mark or name that was the same, or confusingly similar to its mark, such that consumers were likely to confuse the two.’ ”
Tana v. Dantanna’s,
In determining whether a likelihood of confusion exists, the following sev
Defendants do not challenge the validity of Plaintiffs VASER mark. Moreover, Plaintiffs registration certificate constitutes prima facie of its validity, Plaintiffs ownership of the mark, and Plaintiffs exclusive right to use the mark in connection with the goods or services specified in the certificate.
See
15 U.S.C. § 1057(b); 15 U.S.C. § 1115(a);
Applied Info. Sciences Corp. v. eBAY, Inc.,
Furthermore, Defendants do not dispute that the domain names channeled Internet
During oral argument, Defendants advanced a single argument in opposition to Plaintiffs motion. Defendants argued that their use of Plaintiffs marks was authorized. See also Dkt. 22 at 4. As evidence of such authorization, Defendants apparently rely on the LUA and Rubinstein’s averments that (a) SST representatives were aware of and approved (albeit not in writing) Rubinstein’s use of the mark VASER in his advertising materials and on his websites and (b) before Plaintiff filed its application to register the VASER LIPO marks, Goldberger was aware of and consented to Rubinstein’s use of the term VASER LIPO in conjunction with Rubinstein’s use of Plaintiffs VASER System.
“[W]here the trademark holder has authorized another to use its mark, there can be no likelihood of confusion and no violation of the Lanham Act if the alleged infringer uses the mark as authorized.”
Segal v. Geisha NYC LLC,
Defendants contend that Plaintiff unilaterally terminated the LUA without cause. Although the question is unsettled, there is authority for the proposition that a licensor seeking to enjoin continued use of its mark after termination of a licensing
Here, disputed facts preclude a finding, absent an evidentiary hearing,
18
that the LUA was unlawfully terminated (as Rubinstein avers) or expired by its terms (as Plaintiff contends). However, both parties have treated the LUA as terminated or cancelled or avoided or, in short, as no longer in effect. For instance, Defendants returned all the VASER Systems in their possession to Plaintiff. Goldberger Aff. ¶ 3; Sullivan Aff. ¶ 7;
see also
Rubinstein Aff. at 2, 4; Rubinstein Supp. Aff. at 2 (admitting the LUA is “no longer ... in effect”). Defendants were not entitled to treat the LUA as no longer in effect for other purposes but at the same time continue to use Plaintiff’s mark.
Cf. S & R Corp. v. Jiffy Lube Int'l, Inc.,
Words in domain names often communicate information as to the source or sponsor of the associated web site.
(PACCAR Inc. v. TeleScan Tech., L.L.C,
Based on the evidence presented, the Court finds that (1) Plaintiffs VASER mark is fanciful or coined and therefore relatively strong,
see John H. Harland Co. v. Clarke Checks, Inc.,
This evidence sufficiently demonstrates that the domain names as used were likely to confuse or mislead consumers familiar with Plaintiffs VASER System as to Plaintiffs affiliation with or sponsorship of Defendants’ lipoplasty services. Defendants present no evidence that any such confusion would be dispelled by the contents of their website. Although Plaintiff presents no evidence of actual confusion, none is required.
See Montgomery v. Noga,
Without explanation, Sullivan states that Plaintiff first used the VASER LIPO trademark and service mark in commerce on February 15 and October 8, 2008, respectively, Sullivan Aff. ¶ 4;
see also
Dkt. 5 at 11-12. More important here, the registration certificates are evidence of Plaintiffs use of the VASER LIPO trademark and service mark as of the date the applications were filed,
i.e.,
September 22, 2008, and October 10, 2008, respectively.
See
“15 U.S.C. § 1057(c);”
Brookfield Commc’ns,
Rubinstein avers that it was not until after he had combined the terms ‘Vaser” and “Lipo” to create the combination VASER LIPO that Plaintiff applied for and obtained registration of the marks. See Rubinstein Aff. at 2. Moreover, Rubinstein avers that he introduced the term VASER LIPO to the market in January, 2008. Id. Rubinstein apparently did so in connection with his use of Plaintiffs VASER System. See id. (stating that, prior to Plaintiffs application to register the VASER LIPO marks, Goldberger was aware of Rubinstein’s “use of the term ‘VASER LIPO’ in conjunction with [Rubinstein’s] use of Plaintiffs VASER LIPOSELECTION System .... ”).
Even if authorized by the LUA, Rubinstein’s use of the mark in connection with his use of Plaintiffs VASER System would have likely inured to the benefit of Plaintiff.
23
Moreover, to the extent Defendants used the VASER LIPO mark in
Defendants also appear to contend that they were authorized to use the VASER LIPO mark. Rubinstein states that, at some time before Plaintiff filed its applications to register the VASER LIPO marks
(ie.,
before September 22, 2008), Goldberger was aware of and consented to Rubinstein’s use of the term VASER LIPO in conjunction with Rubinstein’s use of Plaintiffs VASER System! However, Rubinstein does not state that Defendants obtained express authorization to register the domain names or to use domain names incorporating the mark to channel Internet traffic to the website for Defendants’ medical practice, and Plaintiff presents evidence to the contrary.
25
Moreover, even if Rubinstein reasonably believed he had implied authorization to use the domain names in this manner, the authorization was expressly withdrawn by June 2008, when Goldberger informed Rubinstein that he was using Plaintiffs mark or marks without permission. Finally, any authorization Defendants had to use the VASER mark was conferred by or within the con
The ACPA
In 1999, Congress passed the Anticybersquatting Consumer Protection Act (“ACPA”), 15 U.S.C. § 1125(d), as an amendment to the Lanham Act to prohibit cybersquatting.
DaimlerChrysler v. The Net Inc.,
A trademark owner asserting a claim under the ACPA must establish that “(1) it has a valid trademark entitled to protection; (2) its mark is distinctive or famous; (3) the defendant’s domain name is identical or confusingly similar to ... the owner’s mark; and (4) the defendant used, registered, or trafficked in the domain name (5) with a bad faith intent to profit.”
DaimlerChrysler v. The Net Inc.,
“Courts generally have held that a domain name that incorporates a trademark is confusingly similar to that mark if consumers might think that [the domain name] is used, approved, or permitted by the mark holder.”
DaimlerChrysler v. The Net Inc.,
As discussed above, Plaintiff presents unrebutted evidence of the validity of the VASER and VASER LIPO marks, and the marks are inherently distinctive. Additionally, the Court finds that the domain names are confusingly similar to Plaintiffs VASER and VASER LIPO marks.
The ACPA sets out nine non-exclusive factors that a court may consider in determining whether a defendant had a bad faith intent to profit. 15 U.S.C. § 1125(d)(l)(B)(i);
see also Southern Grouts & Mortars, Inc. v. SM Co.,
(I) the trademark or other intellectual property rights of the person, if any, in the domain name;
(II) the extent to which the domain name consists of the legal name of the person or a name that is otherwise commonly used to identify that person;
(III) the person’s prior use, if any, of the domain name in connection with the bona fide offering of any goods or services;
(IV) the person’s bona fide noncommercial or fair use of the mark in a site accessible under the domain name;
(V) the person’s intent to divert consumers from the mark owner’s online location to a site accessible under the domain name that could harm the goodwill represented by the mark, either for commercial gain or with the intent to tarnish or disparage the mark, by creating a likelihood of confusion as to the source, sponsorship, affiliation, or endorsement of the site;
(VI) the person’s offer to transfer, sell, or otherwise assign the domain name to the mark owner or any third party for financial gain without having used, or having an intent to use, the domain name in the bona fide offering of any goods or services, or the person’s prior conduct indicating a pattern of such conduct;
(VII) the person’s provision of material and misleading false contact information when applying for the registration of the domain name, the person’s intentional failure to maintain accurate contact information, or the person’s prior conduct indicating a pattern of such conduct;
(VIII) the person’s registration or acquisition of multiple domain names which the person knows are identical or confusingly similar to marks of others that are distinctive at the time of registration of such domain names, or dilutive of famous marks of others that are famous at the time of registration of such domain names, without regard to the goods or services of the parties; and
(IX) the extent to which the mark incorporated in the person’s domain name registration is or is not distinctive and famous within the meaning of subsection (c) of this section.
15 U.S.C. § 1125(d)(l)(B)(i).
A “bad faith intent to profit” may not be found “in any case in which the court determines that the person believed and had reasonable grounds to believe that the use of the domain name was a fair use or otherwise lawful.” See 15 U.S.C. § 1125(d)(l)(B)(ii).
Although discovery may uncover additional evidence relevant to some of the factors, the evidence before the Court tends to show that Defendants have used or trafficked in the domain names with a bad faith intent to profit.
As to factor VI, a bad faith intent to profit from a domain name can arise either at the time of registration or at any time afterwards.
See
McCarthy. § 25:78;
Storey v. Cello Holdings, L.L.C.,
By June 2008, Goldberger informed Rubinstein that he was using Plaintiffs’ mark or marks without permission. Although Rubinstein states that Plaintiff initiated the negotiations to purchase the domain names and Rubinstein at first refused to sell them, this evidence is not dispositive. Rubinstein refused to stop using the domain names and he demanded $200,000 for their transfer. As the practice of holding domain names for ransom with an intent to profit from selling the domain names to the mark owner is “the ‘paradigmatic harm’ targeted by the [ACPA],”
Southern Grouts & Mortars, Inc. v. 3M Co.,
As to factor V, Defendants’ continued unauthorized use of the domain names after the LUA was no longer in effect supports a reasonable inference that Defendants intended to exploit consumer confusion created by the similarity of the domain names to Plaintiffs marks to divert consumers seeking lipoplasty services from Plaintiffs website to Defendants’ website for commercial gain.
In sum, although the question is close and the evidence presented as to the scope of Defendants’ authorization to use Plaintiffs marks is limited, the Court finds that Plaintiff has met its burden of showing a likelihood of success on the merits of its claim under the Anticybersquatting Consumer Protection Act.
Next, even if Plaintiff is not entitled to a presumption of irreparable harm,
26
the
Although Defendants indicated that they have ceased commercial use of the domain names, Defendants’ continued infringement after Plaintiffs cease and desist letters,
see
Goldberger Supp. Aff. ¶2, and retention of the domain names creates a cognizable danger of further violations of the Lanham Act. Additionally, as the ACPA expressly authorizes transfer of a domain name to the owner of the mark after finding an ACPA violation,
see
15 U.S.C. § 1125(d)(1)(C);
see also DaimlerChrysler v. The Net Inc.,
Conclusion
Plaintiffs Motion for Preliminary Injunction (Dkt. 3) is GRANTED in part as follows.
IT IS ORDERED that Defendants are hereby preliminarily enjoined from using Plaintiffs VASER and VASER LIPO marks in any manner in the offer or sale or advertising of any goods or services, including laser-assisted lipoplasty.
IT IS FURTHER ORDERED that Defendant Rubinstein shall forthwith either transfer the domain names vaserlipo.com, vaserlipo.org, vaserlipoinfo, vaser-lipo. com, vaser-lipo.net, vaser-lipo.org, vaserlipoinfo, vaser-lipo.us to Plaintiff or set the domain names to resolve to the IP address for Plaintiffs official website, www.vaser.com, pending a resolution of the merits of this lawsuit.
This preliminary injunction will remain in effect until further notice and at least until Plaintiffs claims are resolved on the merits.
Pursuant to Fed.R.Civ.P. 65(c), as a condition to this injunction, Plaintiff shall post security in the amount of $5,000 on or before August 16, 2010.
Notes
. Although represented by counsel, Defendants filed no memorandum of law in opposition to the motion. See Local Rule 3.01(b) (“Each party opposing a motion ... shall file within fourteen (14) days after service of the motion ... a response that includes a memorandum of legal authority in opposition to the request ....”) (emphasis added).
. April 12, 2010 Affidavit of Daniel S. Goldberger (“Goldberger Aff.” [Dkt. 4]) ¶ 1.
. Plaintiff's registered VASER trademark (Reg. No. 2,441,470, Apr. 3, 2001) covers a “surgical instrument, namely, an ultrasonic surgical system consisting of an ultrasonic surgical instrument to cut, fragment, and coagulate tissue, irrigator, and aspirator ....” Dkt. 5 at 7.
.Plaintiff's registered LIPOSELECTION service mark (Reg. No. 3,000,098, Sept. 27, 2005) covers “medical services in the nature of performing ultrasonic surgical procedures ...." Dkt. 5 at 8.
. See Goldberger Aff. ¶ 3; April 8, 2010 Affidavit of John W. Sullivan ("Sullivan Aff.” [Dkt. 5]) ¶ 7.
. May 25, 2010 Affidavit of Leonard A. Rubinstein, M.D. ("Rubinstein Aff.” [Dkt. 14]) at 4.
. See Sullivan Aff. ¶ 8; June 2, 2010 Supplemental Affidavit of John W. Sullivan ("Sullivan Supp. Aff.” [Dkt. 20]) ¶ 2; see also Goldberger Aff. ¶ 3.
. See May 28, 2010 Supplemental Affidavit of Daniel Goldberger ("Goldberger Supp. Aff.” [Dkt. 17]) V 3.
. June 1, 2010 Supplemental Affidavit of Leonard A. Rubinstein, M.D. (“Rubinstein Supp. Aff.” [Dkt. 19]) at 3. Both parties filed supplemented affidavits after the deadlines set by the May 10, 2010 Order and Local Rule 4.06(b).
. The VASER LIPO marks were not registered until May 26, 2009.
. Rubinstein presents no evidence disputing this assertion. Although stating generally that the assertion "defies explanation," Rubinstein merely avers that he “never received any written communication from Mr. Goldberger or anyone else from the Plaintiff to this effect, prior to [his] receipt of Mr. Goldberger's July 31, 2009 correspondence ----” Rubinstein Supp. Aff. at 1-2 (emphasis added).
. Unlike Section 32(a), Section 43(a) of the Lanham Act protects qualifying unregistered marks.
See Dantanna's,
. Some courts have held that in the Internet context, similarity of the marks, relatedness of the goods or services, and simultaneous use of the Internet as a marketing channel are the most important factors in evaluating the likelihood of confusion.
See GoTo.com v. Walt Disney Co.,
. The Eleventh Circuit adopted as binding precedent, all decisions the former Fifth Circuit made prior to October 1, 1981.
Bonner v. City of Prichard,
.
See Axiom Worldwide,
.
See Axiom Worldwide,
. See also Burger King Corp. v. Mason,
. Neither party requested leave pursuant to Local Rule 4.06(b) to present live testimony or additional evidence at the at the June 2, 2010, hearing.
.
See also PACCAR, Inc. v. Telescan Techs., L.L.C.,
115 F.Supp.2d
111,
777-78 (E.D.Mich.2000) (addition of words such as "trucks,” “used trucks,” and "new trucks” did not eliminate likelihood of confusion with the plaintiff's PETERBILT and KENWORTH trademarks),
aff d in part and vacated in part on other grounds,
. See Rubinstein Aft at 2 (stating that Goldberger was aware of Rubinstein’s "use of the term 'VASER LIPO' in conjunction with [his] use of Plaintiff’s VASER LIPOSELECTION System .... ”).
. To the extent Plaintiff contends that Rubinstein’s registration of the domain names itself violated the Lanham Act, the Court rejects the contention because registration of a domain name, without more, does not constitute commercial use.
See Southern Grouts & Mortars, Inc. v. 3M Co.,
. Plaintiff’s registered VASER LIPO service mark covers "cosmetic surgery, namely, ultrasonic assisted lipoplasty” and disclaims any exclusive right to the term LIPO by itself. Dkt. 5 at 11. Plaintiff's registered VASER LIPO trademark covers an "ultrasonic instrument, namely, an ultrasonic surgical system consisting of an ultrasonic surgical instrument to cut, fragment, and coagulate tissue, irrigator and aspirator” and disclaims any exclusive right to the term LIPO by itself. Dkt. 5 at 13.
.
See
4 McCarthy § 18:45.50 (“[U]se of a designation as a mark by a qualified licensee inures to the benefit of the licensor, who as a result becomes owner of the trademark or service mark rights in the designation.”); 15 U.S.C. § 1055 (“Where a registered mark or a mark sought to be registered is or may be used legitimately by related companies, such use shall inure to the benefit of the registrant or applicant for registration, and such use shall not affect the validity of such mark or of its registration, provided such mark is not used in such manner as to deceive the public. If first use of a mark by a person is controlled by the registrant or applicant for registration
. Rubinstein's contention that he invented the VASER LIPO mark is irrelevant.
See AB Electrolux v. Bermil Indus. Corp.,
. See Sullivan Aff. ¶ 8; Sullivan Supp. Aff. If 2; Goldberger Supp. Aff. ¶ 3. In an August 10, 2009 email message attached to Goldberger’s Supplemental Affidavit, Rubinstein stated to Goldberger: "As you well know, both you and your marketing representative have stated to us on several occasions that we were within our rights to use ‘Vaser’ within any marketing materials. Furthermore, you and your company have been fully aware of our site(s) prior to your company's unilateral decision to transition your marketing approach from 'Liposelective' to 'Vaser Lipo,’ thus copying what we had previously created on our internet marketing program.” (Dkt. 17 at 5-6) (emphasis added). Rubinstein does not repeat the statements in his affidavits.
. In
eBay Inc. v. MercExchange, L.L.C.,
